CUREVAC NV (CVAC) Fundamental Analysis & Valuation
NASDAQ:CVAC • NL0015436031
Current stock price
4.66 USD
-0.01 (-0.21%)
At close:
4.62 USD
-0.04 (-0.86%)
After Hours:
This CVAC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CVAC Profitability Analysis
1.1 Basic Checks
- In the past year CVAC has reported negative net income.
- In the past year CVAC has reported a negative cash flow from operations.
- CVAC had negative earnings in 4 of the past 5 years.
- In multiple years CVAC reported negative operating cash flow during the last 5 years.
1.2 Ratios
- The Return On Assets of CVAC (11.31%) is better than 93.77% of its industry peers.
- CVAC's Return On Equity of 14.79% is amongst the best of the industry. CVAC outperforms 94.53% of its industry peers.
- With an excellent Return On Invested Capital value of 14.12%, CVAC belongs to the best of the industry, outperforming 95.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CVAC has a Profit Margin of 182.11%. This is amongst the best in the industry. CVAC outperforms 98.49% of its industry peers.
- With an excellent Operating Margin value of 212.01%, CVAC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- The Gross Margin of CVAC (93.01%) is better than 93.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. CVAC Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CVAC is creating value.
- The number of shares outstanding for CVAC remains at a similar level compared to 1 year ago.
- CVAC has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for CVAC has been reduced compared to a year ago.
2.2 Solvency
- CVAC has an Altman-Z score of 4.23. This indicates that CVAC is financially healthy and has little risk of bankruptcy at the moment.
- CVAC's Altman-Z score of 4.23 is fine compared to the rest of the industry. CVAC outperforms 71.70% of its industry peers.
- CVAC has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.03, CVAC perfoms like the industry average, outperforming 42.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.23 |
ROIC/WACC1.96
WACC7.21%
2.3 Liquidity
- CVAC has a Current Ratio of 3.70. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
- CVAC's Current ratio of 3.70 is in line compared to the rest of the industry. CVAC outperforms 44.91% of its industry peers.
- A Quick Ratio of 3.69 indicates that CVAC has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.69, CVAC perfoms like the industry average, outperforming 47.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. CVAC Growth Analysis
3.1 Past
- CVAC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -247.92%.
- CVAC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.98%.
- CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
- Based on estimates for the next years, CVAC will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
- The Revenue is expected to decrease by -11.14% on average over the next years. This is quite bad
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. CVAC Valuation Analysis
4.1 Price/Earnings Ratio
- CVAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CVAC is valued cheaply inside the industry as 99.25% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.08 |
4.3 Compensation for Growth
- CVAC's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. CVAC Dividend Analysis
5.1 Amount
- No dividends for CVAC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CVAC Fundamentals: All Metrics, Ratios and Statistics
4.66
-0.01 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24 2025-11-24/bmo
Earnings (Next)04-08 2026-04-08/amc
Inst Owners10.45%
Inst Owner Change-75.38%
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap1.05B
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target5.57 (19.53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)1.84%
Min EPS beat(4)-39.67%
Max EPS beat(4)35.41%
EPS beat(8)3
Avg EPS beat(8)1.3%
EPS beat(12)5
Avg EPS beat(12)-6.32%
EPS beat(16)8
Avg EPS beat(16)6.13%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)16.57%
PT rev (3m)13.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)0%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.77 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.04 | ||
| P/tB | 1.07 | ||
| EV/EBITDA | 3.08 |
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.36
BVpS4.49
TBVpS4.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 4.23 |
F-Score3
WACC7.21%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / CVAC Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to CVAC.
Can you provide the valuation status for CUREVAC NV?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (CVAC). This can be considered as Overvalued.
How profitable is CUREVAC NV (CVAC) stock?
CUREVAC NV (CVAC) has a profitability rating of 5 / 10.
What is the financial health of CUREVAC NV (CVAC) stock?
The financial health rating of CUREVAC NV (CVAC) is 5 / 10.
What is the expected EPS growth for CUREVAC NV (CVAC) stock?
The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -163.99% in the next year.